Johnson & Johnson (JNJ) is Everett Harris & Co. CA’s 9th Largest Position

Everett Harris & Co. CA cut its stake in Johnson & Johnson (NYSE:JNJ) by 0.6% in the second quarter, HoldingsChannel.com reports. The firm owned 934,018 shares of the company’s stock after selling 5,713 shares during the quarter. Johnson & Johnson makes up about 3.1% of Everett Harris & Co. CA’s investment portfolio, making the stock its 9th biggest position. Everett Harris & Co. CA’s holdings in Johnson & Johnson were worth $113,334,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the stock. Palisade Asset Management LLC boosted its holdings in Johnson & Johnson by 3.3% in the second quarter. Palisade Asset Management LLC now owns 129,759 shares of the company’s stock valued at $15,745,000 after purchasing an additional 4,158 shares during the period. Abacus Planning Group Inc. boosted its holdings in Johnson & Johnson by 8.6% in the second quarter. Abacus Planning Group Inc. now owns 9,679 shares of the company’s stock valued at $1,174,000 after purchasing an additional 763 shares during the period. WP Advisors LLC acquired a new stake in Johnson & Johnson in the second quarter valued at $108,000. Peoples Bank OH raised its stake in Johnson & Johnson by 5.6% in the second quarter. Peoples Bank OH now owns 9,335 shares of the company’s stock valued at $1,133,000 after buying an additional 493 shares in the last quarter. Finally, Allen Capital Group LLC raised its stake in Johnson & Johnson by 13.6% in the second quarter. Allen Capital Group LLC now owns 9,947 shares of the company’s stock valued at $1,207,000 after buying an additional 1,190 shares in the last quarter. Hedge funds and other institutional investors own 66.70% of the company’s stock.

Johnson & Johnson stock opened at $137.55 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.33 and a current ratio of 1.65. Johnson & Johnson has a 1-year low of $118.62 and a 1-year high of $148.32. The firm has a market capitalization of $367.48 billion, a price-to-earnings ratio of 18.84, a price-to-earnings-growth ratio of 2.14 and a beta of 0.70.



Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.02. Johnson & Johnson had a return on equity of 34.97% and a net margin of 1.89%. The business had revenue of $20.35 billion for the quarter, compared to analysts’ expectations of $20.05 billion. During the same quarter in the previous year, the firm earned $1.90 earnings per share. The business’s revenue was up 3.6% compared to the same quarter last year. As a group, analysts anticipate that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Tuesday, November 27th will be given a dividend of $0.90 per share. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.62%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 49.32%.

In other news, CAO Ronald A. Kapusta sold 7,899 shares of Johnson & Johnson stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the sale, the chief accounting officer now owns 25,725 shares in the company, valued at $3,528,955.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Michael E. Sneed sold 29,000 shares of Johnson & Johnson stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $134.80, for a total value of $3,909,200.00. Following the sale, the chief operating officer now owns 59,124 shares in the company, valued at approximately $7,969,915.20. The disclosure for this sale can be found here. 0.22% of the stock is currently owned by insiders.

A number of analysts have weighed in on the company. Credit Suisse Group set a $149.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, October 14th. HC Wainwright restated a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, October 17th. Wells Fargo & Co restated an “outperform” rating and issued a $160.00 price target (up from $155.00) on shares of Johnson & Johnson in a research note on Wednesday, October 17th. Jefferies Financial Group set a $145.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, July 15th. Finally, Raymond James raised their price target on Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a research note on Wednesday, October 17th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $142.54.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Index Funds

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply